DermTech (DermTech) Change In Payables And Accrued Expense : $-3.89 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is DermTech Change In Payables And Accrued Expense?

DermTech's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $0.36 Mil. It means DermTech's Accounts Payable & Accrued Expense increased by $0.36 Mil from Dec. 2023 to Mar. 2024 .

DermTech's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-3.08 Mil. It means DermTech's Accounts Payable & Accrued Expense declined by $3.08 Mil from Dec. 2022 to Dec. 2023 .

DermTech Change In Payables And Accrued Expense Historical Data

The historical data trend for DermTech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Change In Payables And Accrued Expense Chart

DermTech Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

1.49

2.47

4.69

2.85

-3.08

DermTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.17	-0.48	-2.36	-1.40	0.36

DermTech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.89 Mil.

DermTech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of DermTech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

DermTech (DermTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037

Website

https://www.dermtech.com

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Executives

Kevin M Sun	officer: Chief Financial Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra	officer: Chief Operating Officer	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan	officer: General Counsel	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard	officer: Chief Commercial Officer	19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood	officer: Chief Commercial Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen	director, officer: Chief Executive Officer	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak	director, officer: Chief Executive Officer	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037